Migraine in children and adolescents is treated in a similar way as in adults. Researchers at the University of Basel, but didn’t come to the conclusion that this may be useful: In this age group, medications for prevention were not in the long term, more effective than a Placebo.
Medications to prevent attacks, are shows for children and young people, apparently, virtually without effect, as a study by the University of Basel: None of the tested drugs was compared to a Placebo in a long-term effect of a half year or longer. Short-term improvements lasting up to five months, were found in children and adolescents only in the case of two agents, Propranolol, and topiramate,.
More studies in children are necessary
So far, the treatment of young patients is based largely on results from studies with adults. The new results show, however, that it is only of limited use in young patients, non-transferable and that further studies on migraine prophylaxis in children and adolescents are required. The authors of the study suggest that the Placebo effect in the younger age group is stronger.
In the context of a network meta-analysis, researchers analyzed 23 studies with a total of more than 2,200 patients. Of these, about a quarter received a Placebo, while the Rest of anti-epileptic drugs, antidepressants, calcium channel blockers, blood pressure-lowering agents or dietary supplements have been treated.